Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2010-06-15
2011-10-25
Ford, Vanessa L. (Department: 1645)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C424S246100, C424S236100, C424S184100
Reexamination Certificate
active
08044189
ABSTRACT:
The invention relates to improved methods of producing and recoveringB. anthracisprotective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of,B. anthracisbacterial infections and which are useful to prevent and/or treat illnesses caused byB. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.
REFERENCES:
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 4038142 (1977-07-01), Turcotte et al.
patent: 5210035 (1993-05-01), Stocker
patent: 5591631 (1997-01-01), Leppla et al.
patent: 5677274 (1997-10-01), Leppla et al.
patent: 5747309 (1998-05-01), Allan et al.
patent: 5840312 (1998-11-01), Mock et al.
patent: 6267966 (2001-07-01), Baillie
patent: 6316006 (2001-11-01), Worsham et al.
patent: 6387665 (2002-05-01), Ivins et al.
patent: WO 01/21656 (2001-03-01), None
patent: WO 01/82788 (2001-11-01), None
Ramirez et al (Abstract of SIM Meeting, Nov. 2001).
Ellis (Vaccines, W.B. Saunders Company, Chapter 29, 1988, pp. 568-574).
Boslego et al (Vaccines and Immunotherapy, 1991, Chapter 17).
Baillie et al., “The expression of the protective antigen ofBacillus anthracisinBacillus subtilis,” J. Appl. Microbiol. 84:741-746, 1998.
Bartkus et al., “Transcriptional regulation of the protective antigen gene ofBacillus anthracis,” Infect. Immun. 57:2295-2300, 1989.
Bowie et al., “Decipering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science247:1306-1310, 1990.
Chase, H.A., “Purification of proteins by adsorption chromatography in expanded beds,”Trends Biotechnol. 12:296-303, 1994.
Chauhan et al., “Constitutive expression of protective antigen gene ofBacillus anthracisinEscherichia coli,” Biochem. Biophys. Res. Commun. 283:308-315, 2001.
Chu et al., “Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide ofShigella dysenteriaetype 1 (Shiga'sBacillus) bound to tetanus toxoid,”Infect. Immun. 59:4450-4458, 1991.
Coulson et al., “Bacillus anthracisprotective antigen, expressed inSalmonella typhimuriumSL 3261, affords protection against anthrax spore challenge,”Vaccine12:1395-1401, 1994.
Creighton, Thomas E., in his book, “Proteins: Structures and Molecular Properties,” 1984 (pp. 314-315).
Creighton, Thomas E., in his book “Protein Structure: A Practical Approach,” 1989, (pp. 184-186).
de Veth and Kolver, “Digestion of Ryegrass Pasture in Response to Change in pH in Continuous Culture,”J. Dairy Sci. 84:1449-1457, 2001.
Ezzell and Welkos, “The capsule ofBacillus anthracis, a review,”J. Appl. Microbiol. 87:250, 1999.
Farchaus et al., “Purification and characterization of the major surface array protein from the avirulentBacillus anthracisDelta Sterne-1,”J. Bacteriol. 177:2481-2489, 1995.
Farchaus et al., “Fermentation, purification, and characterization of protective antigen from a recombinant, avirulent strain ofBacillus anthracis,” Appl. Environ. Microbiol. 64:982-991, 1998.
Fellows et al., “Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge byBacillus anthracisisolates of diverse geographical origin,”Vaccine19:3241-3247, 2001.
Fouet et al., “Bacillus anthracissurface: capsule and S-layer,”J. Appl. Microbiol. 87:251-255, 1999.
Gladstone, “Immunity to anthrax: protective antigen present in cell-free culture filtrates,”Br. J. Exp. Pathol. 27:394-418, 1946.
Glick and Pasternak, Molecular Biology Principles and Applications of Recombinant DNA, American Society for Microbiology, pp. 311-312, 1994.
Gupta et al., “Expression and purification of the recombinant protective antigen ofBacillus anthracis,” Protein Expr. Purif. 16:369-376, 1999.
Gupta et al., “Enhanced expression of the recombinant lethal factor ofBacillus anthracisby Fed-Batch culture,”Biochem. Biophys. Res. Commun. 285:1025-1033, 2001.
Hambleton and Turnbull, “Anthrax vaccine development: a continuing story,”Bacterial Vaccines13:105-122, 1990.
Hemilä et al., “Improving the production ofE. coliβ-lactamase inBacillus subtilis: the effect of glucose, pH and temperature on the production level,”J. Biotechnol. 26:245-256, 1992.
Iacono-Connors et al., “Expression of theBacillus anthracisprotective antigen gene by baculovirus and vaccinia virus recombinants,”Infect. Immun. 58:366-372, 1990.
Ivins et al., “Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques,”Vaccine16:1141-1148, 1998.
Ivins and Welkos, “Cloning and expression of theBacillus anthracisprotective antigen gene inBacillus subtilis,” Infect. Immun.. 54:537-542, 1986.
Khanna et al., “Participation of Residue F552in Domain III of the Protective Antigen in the Biological Activity of Anthrax Lethal Toxin,”Biol. Chem. 382:941-946, 2001.
Keppie et al., “The chemical basis of the virulence ofBacillus anthracis,IX. Its aggressins and their mode of action,”Br. J. Exp. Pathol. 44:446-453, 1963.
Kossaczka et al., “Synthesis and immunological properties of Vi and Di-O-Acetyl pectin protein conjugates with adipic acid dihydrazide as the linker,”Infect. Immun. 65:2088-2093, 1997.
Leppla, “Production and purification of anthrax toxin,”Methods Enzymol. 165:103-116, 1988.
Leppla, “The anthrax toxin complex,” In: Sourcebook of bacterial protein toxins (Alouf and Freer, eds.), pp. 277-302, Academic Press, Inc., San Diego, CA, 1991.
Leppla, “Anthrax toxins,” In: Bacterial toxins and virulence factors in disease, Handbook of natural toxins (Moss et al., eds.), pp. 543-572, Dekker, New York.
Leppla, “A dominant-negative therapy for anthrax,”Nature Med. 7:659-660, 2001.
Little et al., “Passive protection by polyclonal antibodies againstBacillus anthracisinfection in guinea pigs,”Infect. Immun. 65:5171-5175, 1997.
Liu et al., “Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin,”J. Biol. Chem276:17976-17984, 2001.
Liu et al., “Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin,”Cancer Res. 60:6061-6067, 2000.
Mancini et al., “Immunological quantitation of antigens by single radial immunodiffusion,”Immunochemistry2:235-254, 1965.
Miller et al., “Production and purification of recombinant protective antigen and protective efficacy againstBacillus anthracis,” Lett. Appl. Microbiol. 26:56-60, 1998.
Mock and Fouet, “Anthrax,”Annu. Rev. Microbiol. 55:647-671, 2001.
Nosoh et al., “Protein Stability and Stabilization through Protein Engineering,” 1991 (chapter 7, p. 197, second paragraph).
Park and Leppla, “Optimized production and purification ofBacillus anthracislethal factor,”Protein Express. and Purif. 18:293-302, 2000.
Price et al., Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein,Infect. Immun. 69:4509-4515, 2001.
Puziss et al., “Large-scale production of protective antigen ofBacillus anthracisanaerobic cultures,”Appl. Microbiol. 11:330-334, 1963.
Ramirez et al., Abstract of SIM Meeting, Nov. 1, 2001.
Ramirez et al., “Production, recovery and immunogenicity of the protective antigen from a recombinant strain ofBacillus anthracis,” J. Indus. Microbiol. Biotechnol. 28:232-238, 2002.
Reuveny et al., “Search for correlates of protective immunity conferred by anthrax vaccine,”Infect. Immun. 69:2888-2893, 2001.
Sharma et al., “Expression and purification of
Klimpel Kurt
Leppla Stephen H.
Robbins John B.
Schneerson Rachel
Singh Yogendra
Ford Vanessa L.
Klarquist & Sparkman, LLP
The United States of America as represented by the Department of
LandOfFree
Bacillus anthracis protective antigen nucleic acid sequences does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bacillus anthracis protective antigen nucleic acid sequences, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bacillus anthracis protective antigen nucleic acid sequences will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4300619